Norway seeks to ease rules on biomaterials exchange
This article was originally published in Clinica
Executive Summary
At the start of December, the Norwegian health department will send a copy of its draft proposals regulating the transfer of biological material to and from foreign biobanks to healthcare institutions, industry associations and local authorities for evaluation. The aim is to ease these regulations in cases where international co-operation will not conflict with national interests or the protection of privacy.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.